Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck

NCT03132038 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03132038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03132038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2017
Completion date
October 20, 2021
Enrollment
98 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer, recurrent cancer, salivary gland carcinoma